Flash of hope: millisecond radiation could spare healthy skin in cancer fight

NCT ID NCT07455331

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new type of radiation called FLASH therapy, which delivers the entire dose in milliseconds instead of minutes. The goal is to see if it can treat skin cancers (squamous cell and basal cell carcinomas) just as well as standard radiation but with fewer side effects on healthy skin. About 60 people aged 60 or older who cannot have or decline surgery will receive either FLASH or conventional radiation, and researchers will monitor side effects and tumor control for one year.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
FLASH radiotherapy (ultra-fast radiation delivered in milliseconds)
What this could lead to
If successful, FLASH radiotherapy could offer a quicker, less damaging treatment for skin cancers, reducing side effects on healthy tissue while still curing the cancer.
What could go wrong
This is an early phase II trial with only 60 participants, so results may not apply to everyone. FLASH is experimental and its long-term safety and effectiveness compared to standard care are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Signed study Informed Consent Form 2. Karnofsky Performance Status (KPS) ≥ 60 3. Age ≥ 60 years 4. Participants with histologically proven cSCC; or participants with BCC either histologically proven or proven by non-invasive imaging: either OCT, LC-OCT or RCM 5. Participants requiring radiotherapy treatment according to the dermato-oncology tumor board: participants who cannot undergo surgical procedure or participants who decline surgical resection, and/or anatomical locations where surgery can compromise function or cosmesis. 6. T1-N0 lesions (TNM UICC, 8th Edition) 7. Lesions should be at least 4 cm apart if treated with 2 different modalities (including surgical treatment of lesions). Lesions should not be located on the face, except on the forehead, above a line situated 1 cm above the eyebrows. Lesions located on the scalp can be treated 8. In cases of prior intervention within the target area, the treated lesion must be located at a distance of \> 4 cm from the previous site. Exclusion Criteria: 1. Previous radiotherapy in the treated area or a history of radiation therapy within 4 cm of the lesion to be treated 2. Concomitant auto-immune disease with skin lesions 3. Concomitant use of radio-sensitizer drug 4. Cognitive disorders not compatible with the signature of informed consent or that may compromise compliance with the requirements of the study 5. Current, recent (within 10 days prior to start of study treatment), or planned participation in an experimental drug study (before EOT visit) 6. Concomitant use of systemic or immunochemotherapy for skin cancer(s) 7. Concomitant use of systemic chemotherapy for a cancer other than the skin cancer(s) 8. Topical antitumoral treatment is prohibited within the radiation field except after a mandatory 4-weeks washout period. 9. Any active cutaneous infection within the irradiation field (except if completely resolved prior to the initiation of radiotherapy). 10. Uncontrolled intercurrent comorbidities that may impair wound healing including Diabetes Mellitus (HbA1c \> 8.5% or evidence of active diabetic ulceration), Chronic Venous Insufficiency with active venous ulcers, or severe (Grade 3+) oedema in the treatment field.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Basal cell carcinoma (BCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Institut Jules Bordet

    Brussels, Anderlecht, 1070, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.